Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(12):892-893; doi:10.1093/jnci/93.12.892
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 12, 892-893, June 20, 2001
© 2001 Oxford University Press

NEWS

Cancer Fatigue: One Drug Fails But More Are in the Pipeline

Caroline McNeil

The hypothesis made sense, and the drug was promising.

The hypothesis was that reducing depression could also reduce fatigue in cancer patients, based on the widespread observation that the two often coexist. The drug was paroxetine (Paxil®), and there was a feasible biologic model showing how serotonin might play a role in cancer-related fatigue.

"It all made perfect sense," said Gary Morrow, Ph.D., of the University of Rochester, N.Y., who led a large, randomized trial to test the hypothesis. "It seemed to fit a lot of what we had observed and a lot of what we know. It just happened not to be accurate."


Figure Removed (Available Only in the Full Text)
View larger version (146K):
[in this window]
[in a new window]
  		Dr. Gary Morrow

 
The patients who took . . . [Full Text of this Article]

More in Pipeline

Steroids

Other Psychostimulants

Nonpharmacologic Approaches


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?